Company intelligence / Profile preview

VenoStent

Houston, Texas, United Statesvenostent.com ↗

Ownership: Private
Development stage: Phase 2

Overview

VenoStent’s SelfWrap has shown promising results in early human studies and feasibility trials, demonstrating improved arteriovenous fistula maturation and durability for dialysis patients. The company is currently running a large, multi-center randomized controlled trial funded by a $3.6 million NIH SBIR grant to further validate safety and efficacy. Initial feasibility studies have been completed with positive outcomes.

Therapeutic areas: Nephrology
Modalities: DeviceBiomaterial platformBioabsorbable polymer wrapShape memory polymer device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

SelfWrap

Phase 2

Indications: End-stage renal disease, Chronic kidney disease

Partnerships

National Institutes of Health (NIH) – SBIR grant funding partner

Beyond the preview

Go deeper on VenoStent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VenoStent.

Explore the full profile